Relationship of Oxidized Phospholipids on Apolipoprotein B-100 to Cardiovascular Outcomes in Patients Treated With Intensive Versus Moderate Atorvastatin Therapy The TNT Trial by Byun, Young Sup et al.
J O U R N A L O F T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y V O L . 6 5 , N O . 1 3 , 2 0 1 5
ª 2 0 1 5 B Y T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N D A T I O N I S S N 0 7 3 5 - 1 0 9 7 / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C . h t t p : / / d x . d o i . o r g / 1 0 . 1 0 1 6 / j . j a c c . 2 0 1 5 . 0 1 . 0 5 0Relationship of Oxidized Phospholipids
on Apolipoprotein B-100 to
Cardiovascular Outcomes in Patients
Treated With Intensive Versus
Moderate Atorvastatin Therapy
The TNT TrialYoung Sup Byun, MD,*y Jun-Hee Lee, MD, PHD,*z Benoit J. Arsenault, PHD,x Xiaohong Yang, BS,*
Weihang Bao, PHD,k David DeMicco, PHARMD,k Rachel Laskey, PHD,k Joseph L. Witztum, MD,{ Sotirios Tsimikas, MD,*
for the TNT Trial InvestigatorsABSTRACTFro
De
Ca
l’In
Ne
su
an
an
NaBACKGROUND Oxidized phospholipids on apolipoprotein B-100 (OxPL-apoB) is a biomarker of increased risk for major
adverse cardiovascular events (MACE) in community cohorts, but its role in patients with stable coronary heart disease
(CHD) is unknown.
OBJECTIVES This study sought to examine the relationship between these oxidative biomarkers and cardiovascular
outcomes in patients with established CHD.
METHODS In a random sample from the TNT (Treating to New Targets) trial, OxPL-apoB levels were measured
in 1,503 patients at randomization (after an 8-week run-in period taking atorvastatin 10 mg) and 1 year after being
randomized to atorvastatin 10 or 80 mg. We examined the association between baseline levels of OxPL-apoB and MACE,
deﬁned as death from CHD, nonfatal myocardial infarction, resuscitation after cardiac arrest, and fatal/nonfatal stroke, as
well as the effect of statin therapy on OxPL-apoB levels and MACE.
RESULTS Patients with events (n ¼ 156) had higher randomization levels of OxPL-apoB than those without events
(p ¼ 0.025). For the overall cohort, randomization levels of OxPL-apoB predicted subsequent MACE (hazard ratio [HR]:
1.21; 95% conﬁdence interval: 1.04 to 1.41; p ¼ 0.018) per doubling and tertile 3 versus tertile 1 (hazard ratio: 1.69; 95%
conﬁdence interval [CI]: 1.14 to 2.49; p ¼ 0.01) after multivariate adjustment for age, sex, body mass index, among
others, and treatment assignment. In the atorvastatin 10-mg group, tertile 3 was associated with a higher risk of MACE
compared to the ﬁrst tertile (HR: 2.08; 95% CI: 1.20 to 3.61; p ¼ 0.01) but this was not signiﬁcant in the atorvastatin
80-mg group (HR: 1.40; 95% CI: 0.80 to 2.46; p ¼ 0.24).
CONCLUSIONS Elevated OxPL-apoB levels predict secondary MACE in patients with stable CHD, a risk that is mitigated
by atorvastatin 80 mg. (A Study to Determine the Degree of Additional Reduction in CV Risk in Lowering LDL Below
Minimum Target Levels [TNT]; NCT00327691) (J Am Coll Cardiol 2015;65:1286–95) © 2015 by the American College of
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1287AB BR E V I A T I O N S
AND ACRONYM S
apoB = apolipoprotein B-100
CHD = coronary heart disease
LDL-C = low-density
lipoprotein cholesterol
Lp(a) = lipoprotein(a)
MACE = major adverse cardiac
event(s)
OSE = oxidation-speciﬁc
epitope
OxPL = oxidized phospholipids
PC = phosphocholineA therosclerosis is a chronic inﬂammatory dis-ease whose pathogenesis is stronglymediatedby dyslipidemia and other risk factors acti-
vating both innate and adaptive immune systems
to generate chronic proinﬂammatory responses (1).
Lipoprotein oxidation generates so-called “oxidation-
speciﬁc epitopes” (OSEs) that are an important, if not
obligatory, intermediary between dyslipidemia, in-
ﬂammation, and initiation and progression of athero-
sclerotic lesions. Clinical events ultimately result from
the interaction of lipid accumulation, OSE generation,
activation of inﬂammatory processes, recruitment
of inﬂammatory cells to the vessel wall, endothelial
dysfunction, platelet activation, and thrombosis.SEE PAGE 1296These OSEs represent a major class of atherosclerosis-
relevant antigens that deﬁne oxidative modiﬁcations
on low-density lipoprotein cholesterol (LDL-C) parti-
cles, apoptotic cells, and proteins in the vessel wall (2).
They are present both in the lipid phase as oxidized
lipids and as oxidized lipids covalently bound
to apolipoprotein B-100 (apoB) or other proteins.
OSEs share molecular or immunological identity with
danger-associated molecular patterns (known as
DAMPs) on apoptotic cells and oxidized LDL-C, as well
as pathogen-associated molecular patterns (or PAMPs)
on microbial pathogens. Oxidation-speciﬁc epitopes
are recognized by a common set of innate pattern
recognition receptors, which have been evolutionary
selected to protect against the proinﬂammatory prop-
erties of OSEs.
Phosphocholine (PC)-containing oxidized phos-
pholipids (OxPL) are well-studied OSEs that are
highly immunogenic, proinﬂammatory, and present
in atherosclerotic lesions of animals and humans,
particularly in pathologically-deﬁned vulnerable and
disrupted plaques (3). OxPLs are important contrib-
utors to early and late events in atherogenesis by
activating proinﬂammatory genes in endothelial cells
and macrophages (4), leading to inﬂammatory cas-
cades in the vessel wall (5). Lipoprotein(a) [Lp(a)] is
the major lipoprotein carrier of OxPL, which may
impart pro-inﬂammatory properties (6,7). OxPL can be
measured on apoB-100 lipoproteins (OxPL-apoB;and P01-HL055798; and are coinventors and receive royalties from patents o
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containing oxidized phospholipids [PC-OxPL]
per unit of apoB) in plasma with the murine
natural antibody E06. OxPL-apoB levels have
been shown to correlate with the presence of
anatomical cardiovascular disease (CVD) (8)
and events in clinical studies in community-
based settings in patients generally without
prior coronary heart disease (CHD) (9,10).
The ability of OxPL-apoB to predict risk of
angiographically-determined coronary artery
disease (CAD) and CVD events is strongly
potentiated by interleukin-1 genotypes that
are associated with genetically-elevated pre-
disposition to inﬂammation (11).
E06 binds to the PC headgroup of a variety of OxPL,
but does not recognize phospholipids on unoxidized
phospholipids or non–PC-oxidized phospholipids
(12). Clinical outcome studies using alternative
methods to measure OxPL, such as tandem liquid
chromatography/mass spectrometry, have not been
performed due to the laborious need to quantitate the
multiple OxPL species and the lack of appropriate
standards. Our group recently documented the pres-
ence of OSE in progressive coronary and carotid
atheromata (3) and speciﬁc E06 and non-E06 detect-
able OxPL and oxidized cholesteryl esters by tandem
liquid-chromatography/mass spectrometry in debris
captured by distal protection devices in patients
undergoing coronary or peripheral procedures, doc-
umenting their relevance to clinical disease (13,14).
The relationship of these oxidative biomarkers to
cardiovascular outcomes in patients with established
CHD is not deﬁned. The aim of this study, therefore,
was to assess the effect of low- versus high-dose
statin therapy on OxPL-apoB levels in such patients
and their relationship to subsequent major adverse
cardiac events (MACE).
METHODS
STUDY DESIGN. This substudy is on the basis of
a random sample from the TNT (Treating to New
Targets) study population, a randomized trial that
compared the efﬁcacy of high-dose (80 mg) versuswned by UCSD on oxidation-speciﬁc antibodies and
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1288low-dose (10 mg) atorvastatin for secondary preven-
tion of CHD (15). Importantly, for this substudy, blood
samples were obtained at randomization, which
occurred after an 8-week run-in period on atorvastatin
10mg, and again 1 year after being randomized to 10mg
or 80mg atorvastatin. This substudy consisted of 1,503
patients, of whom 1,347 did not experience an event
and 156 had a documented MACE during the 4.9 years
of study follow-up. MACE was deﬁned as CVD death,
nonfatal/nonprocedure-relatedmyocardial infarction,
resuscitated cardiac arrest, and fatal or nonfatal
stroke.
OxPL-apoB levels were measured in a chemilumi-
nescent immunoassay using the murine monoclonal
antibody E06 that recognizes the PC group on
oxidized but not on native phospholipids (Taleb et al.
[8] and references therein). In prior studies, this
variable was expressed as OxPL/apoB, reﬂecting the
fact that this measure quantitates the number of
OxPL moles per unit mass of apolipoprotein B-100
present on microtiter well plates (and not the level in
the circulation). The nomenclature is now changed to
OxPL-apoB to minimize confusion that this measure
represents a ratio of OxPL divided by plasma levels of
apoB. Details of the OxPL-apoB assay are provided
in the Online Appendix. The Lp(a) levels were
measured by a latex immunoturbidimetric assay
(Wako Chemicals USA, Inc., Richmond, Virginia) (16).
STATISTICAL ANALYSIS. Patient demographics and
disease characteristics at randomization were com-
pared between treatment groups using a chi-square
test for categorical variables and a Wilcoxon rank
sum test for continuous variables. Similar compari-
sons were conducted between those who did and did
not experience an event. Results in OxPL-apoB were
also conﬁrmed in a Student t test after a log trans-
formation. The distribution of OxPL-apoB was highly
skewed, but the normality was greatly improved
after the log transformation. Changes from randomi-
zation (i.e., after 8 weeks of open-label run-in treat-
ment with atorvastatin 10 mg) to 1 year in OxPL-apoB
were tested with a Wilcoxon signed rank test and
compared with a Wilcoxon rank sum test between
treatment groups and between patients with and
without a clinical outcome. Spearman correlation
was calculated to assess association between ran-
domization and 1 year OxPL-apoB as well as between
OxPL-apoB and lipid and other nonlipid biomarkers.
The association between on-treatment OxPL-apoB
(at time of randomization and at 1 year) and a MACE
endpoint were assessed in a Cox proportional hazards
model after adjustment for age, sex, and treatment
effect; using time to cardiovascular endpoint as thedependent variable; and for all patients and for
patients within each treatment group. First, OxPL-
apoB was used as a continuous variable, with log2
transformation. Then, OxPL-apoB was ranked into
tertiles and expressed as 3 dummy indicator variables
using the ﬁrst tertile as the control. Treatment by
OxPL-apoB interaction was examined separately in
the same model with the addition of interaction term.
The proportional hazards assumption was examined
and conﬁrmed not to be violated by looking at the
supremum test and the cumulative martingale re-
siduals. All analyses were performed using SAS soft-
ware, version 9 (SAS Institute, Cary, North Carolina).
In a simple Student t test with an observed SD of
4.16 nmol/l PC-OxPL, a sample size of 1,500 patients
has 80% power to detect a difference of 0.15 SD (0.62
nmol/l) between the 2 treatment groups, or a differ-
ence of 0.24 SD (1.00 nmol/l) between patients who
did and did not experience a primary endpoint event
during the study, given the event rate of 10%. Alter-
natively, because PC-OxPL is log-transformed before
analyses, on a log2 scale, the SD is 1.043. Using a
Student t test on the basis of a log-transformed data,
a sample size of 1,500 has 80% power to detect an
11.5% difference between the 2 treatment groups, or
19.1% difference between patients who did and did
not experience a primary endpoint event during the
study, given the event rate of 10%.
RESULTS
The characteristics of patients in the main study and
in the biomarker substudy at the time of randomiza-
tion are shown in Table 1. In the biomarker study, 1,503
patients were included, of whom 754 were treated
with atorvastatin 10 mg and 749 with atorvastatin 80
mg. Of these subjects, 156 had an MACE and 1,347 had
no event. Patients with MACE were older; were more
likely to have hypertension, to have diabetes, or to be
current smokers; and had lower high-density lipo-
protein cholesterol (HDL-C), but similar LDL-C and
Lp(a) levels. At randomization, OxPL-apoB levels were
not signiﬁcantly different between atorvastatin 10 and
80 mg. However, patients with events had higher
levels of OxPL-apoB at randomization than those
without events:median interquartile range: 4.4 nmol/l
(quartile [Q]1 2.7, Q3 7.9 nmol/l) versus 3.7 nmol/l (Q1
2.3, Q3 6.8 nmol/l) PC-OxPL (p¼ 0.025) (Table 1). These
ﬁndings on OxPL-apoB were conﬁrmed in a Student
t test on the basis of a log-transformed OxPL-apoB.
Patients with events had 14.5% higher OxPL-apoB
level, or 0.195 higher on a log2 scale, than those
without events (p ¼ 0.027). No signiﬁcant difference
was observed between treatment groups.
TABLE 1 Patient Characteristics at Randomization*
Main Study Biomarker Substudy
By Treatment
All Patients
(n ¼ 1,503)
By Treatment By Event
ATV 10 mg
(n ¼ 5,006)
ATV 80 mg
(n ¼ 4,995)
ATV 10 mg
(n ¼ 754)
ATV 80 mg
(n ¼ 749)
With Event
(n ¼ 156)
Without Event
(n ¼ 1,347) p Value†
Age, yrs 60.9  8.8 61.2  8.8 61.5  8.7 61.3  8.5 61.8  8.9 62.8  8.5 61.4  8.7 0.034
Male 80.8 81.2 78.8 80.1 79.7 83.3 78.3 0.14
Risk factor
Current smoker 13.4 13.4 12.4 14.6 11.2 18.6 11.7 0.034
Hypertension 54.4 53.9 57.7 58.4 55.9 69.2 56.4 0.002
Diabetes 15.0 15.0 16.6 16.9 16.3 26.3 15.5 0.0006
Lipids
LDL cholesterol, mg/dl 98  18 98  17 98  18 98  18 97  18 98  18 98  18 0.91
Total cholesterol, mg/dl 175  24 175  24 175  24 175  23 175  25 175  23 175  24 0.96
Triglycerides, mg/dl 134 (101–184) 135 (102–183) 138 (106–189) 142 (106–191) 136 (106–185) 139 (110–200) 138 (105–187) 0.27
HDL cholesterol, mg/dl 47  11 47  11 47  11 46  11 47  11 44  10 47  11 0.0007
Lp(a), mg/dl — — 15 (5–39.5) 15 (5–42) 14 (5–37) 20 (5–47.5) 14 (5–38) 0.104
OxPL-apoB, nmol/l — — 3.8 (2.4–6.9) 3.8 (2.4–7.0) 3.7 (2.3–6.9) 4.4 (2.7–7.9) 3.7 (2.3–6.8) 0.025
Values are mean  SD, %, or median (interquartile range) unless otherwise indicated. *At the time of randomization, all participants had received atorvastatin 10 mg for 8 weeks. †p value for patients who
experienced an event versus those who did not in the biomarker subgroup.
ATV ¼ atorvastatin; HDL ¼ high-density lipoprotein; LDL ¼ low-density lipoprotein; Lp(a) ¼ lipoprotein(a); OxPL-apoB ¼ oxidized phospholipids on apolipoprotein B-100.
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1289In the overall cohort, the level of OxPL-apoB at
randomization (after the 8-week run-in period with
atorvastatin 10 mg) predicted recurrent events. The
hazard ratio (HR) associated with doubling of the
OxPL-apoB concentration was 1.20 (95% conﬁdence
interval [CI]: 1.03 to 1.39; p ¼ 0.018) after adjusting for
age, sex, and treatment (Table 2). The difference in
the atorvastatin 10-mg group remained signiﬁcant
(HR: 1.23; 95% CI: 1.00 to 1.51; p ¼ 0.05), whereas in
the atorvastatin 80-mg group, it lost signiﬁcance (HR:
1.17; 95% CI: 0.94 to 1.46; p ¼ 0.16). Treatment
interaction by OxPL-apoB levels at randomization did
not reach statistical signiﬁcance, likely due to the fact
that the test of interaction often requires a much
larger sample size. The 1-year OxPL-apoB levels and
the change from randomization to 1 year in OxPL-
apoB levels were not associated with higher risk of
recurrent events for the overall, atorvastatin 10-mg,
or atorvastatin 80-mg groups.TABLE 2 Association Between Randomization, 1 Year, Change from R
All Patients
HR† 95% CI p Value
Randomization 1.20 1.03–1.39 0.018
Year 1 1.15 0.96–1.38 0.143
Change from randomization to year 1 0.93 0.74–1.17 0.523
*At the time of randomization, all participants had received 10 mg atorvastatin for 8 we
age, sex, and treatment effect. Treatment interaction by individual biomarker is not sign
CI ¼ conﬁdence interval; other abbreviations as in Table 1.The ﬁndings between randomization levels of
OxPL-apoBandsubsequentMACEremainedconsistent
after further adjustment for all traditional risk factors
including age, sex, body mass index (BMI), diabetes
mellitus, systolic blood pressure (SBP), LDL-C, HDL-C,
ApoB, and treatment (HR: 1.21; 95% CI: 1.04 to 1.41;
p ¼ 0.018) per doubling of OxPL-apoB concentra-
tion in the total population. This remained signiﬁ-
cant in the atorvastatin 10-mg group (HR: 1.28; 95%
CI: 1.03 to 1.58; p ¼ 0.028), but not the atorvastatin
80-mg group (HR: 1.16; 95% CI: 0.93 to 1.44;
p ¼ 0.19).
Evaluating groups by tertiles (Figure 1), tertile 3
was associated with a higher risk of MACE compared
with the ﬁrst tertile in the overall group (HR: 1.69;
95% CI: 1.14 to 2.49; p ¼ 0.01) and in the atorvastatin
10-mg group (HR: 2.08; 95% CI: 1.20 to 3.61; p ¼ 0.01).
This was not signiﬁcant in the atorvastatin 80-mg
group (HR: 1.40; 95% CI: 0.80 to 2.46; p ¼ 0.24).andomization to 1 Year in OxPL-apoB, and Clinical Outcomes*
Atorvastatin 10 mg Atorvastatin 80 mg
HR† 95% CI p Value HR† 95% CI p Value
1.23 0.99–1.51 0.053 1.17 0.94–1.46 0.156
1.22 0.95–1.58 0.127 1.06 0.81–1.38 0.670
0.95 0.68–1.31 0.736 0.90 0.65–1.23 0.503
eks. †Hazard ratio (HR) associated with doubling the concentration and adjusting for
iﬁcant for all biomarkers analyzed.
FIGURE 1 Association Between OxPL-apoB Levels at Randomization and Subsequent Major Cardiovascular Events
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1290The treatment by OxPL-apoB interaction was not
signiﬁcant (p ¼ 0.37).
To test the robustness of our results, we also per-
formed a logistic regression analysis looking at the
proportion of patients within the total study popula-
tion who experienced a MACE during the study. Afterin OxPL-apoB Levels From Randomization to 1 Year
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solute changes in OxPL-apoB levels are shown according to
and (B) whether the patient experienced a major cardiovascular (CV)
are from comparisons using the 2-sided Wilcoxon rank sum test.
igure 1.adjusting for age, sex, and treatment group, OxPL-
apoB signiﬁcantly predicted MACE as expected. The
odds ratio (OR) associated with doubling the concen-
tration of OxPL-apoB was 1.21 (95% CI: 1.03 to 1.42; p ¼
0.021). A receiver-operating characteristics (ROC)
analysis was also performed, showing that the area
under the ROC curve increased from 0.5735 to 0.5868
by adding OxPL-apoB to the model. However, this in-
crease of 0.0133 was not statistically signiﬁcant (95%
CI: 0.0175 to 0.0440; p ¼ 0.39). The incremental area
under ROC remained nonsigniﬁcant when it was
added to the model of other traditional risk factor
variables, including baseline levels of LDL-C, HDL-C,
apoB, SBP, BMI, and diabetes mellitus. Nevertheless,
this nonsigniﬁcance of incremental area under the
ROC curve does not negate the potential prognostic
value of OxPL-apoB for subsequentMACE, because the
well-established traditional risk factors also failed to
show a signiﬁcant incremental area under ROC to
predict MACE when analyzed in the same model.
However, like OxPL-apoB, traditional risk factors
including age, BMI, diabetes mellitus, SBP, and HDL-C
were all signiﬁcant predictors in both the Cox pro-
portional hazard and the logistic regression analyses,
but failed to achieve signiﬁcant incremental area un-
der ROC. Further research is needed to validate the
utility of the ROC analytical approach in such cir-
cumstances. Likely due to their strong correlation,
neither OxPL-apoB nor Lp(a) were signiﬁcant pre-
dictors when both were included in the Cox propor-
tional hazard analysis. We had previously reported the
prognostic value of OxPL-apoB in primary prevention
settings by showing that it reclassiﬁes w30% of
patients from the general community using c-statistics
and net reclassiﬁcation measures (17).
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1291In the overall cohort, the median percent change in
OxPL-apoB levels from randomization to 1 year was
3.5% (IQR: 28.9% to þ45.1%) (Figure 2A). In the
atorvastatin 10-mg group, there was no signiﬁcant
change in the median percent change (0.5%;
IQR: 30.8% to þ36.7%; p ¼ 0.061). However, in the
atorvastatin 80-mg group, there was a signiﬁcant
increase in the median percent change at 8.0%
(IQR: 26.9% to þ53.3%; p < 0.0001). This treat-
ment group difference was statistically signiﬁcant
(p ¼ 0.0089). Similar ﬁndings were present in the
changes of absolute levels of OxPL-apoB (Figure 2A).
In patients with recurrent events, the median
percent change in OxPL-apoB levels from randomi-
zation to 1 year was 7.6% (IQR: 35.5% to þ49.5%;
p ¼ 0.34) (Figure 2B). In patients who did not expe-
rience an event, there was a signiﬁcant increase in
the median change at 5.0% (IQR: 27.7% to þ43.8%;
p < 0.0001). However, the differences between pa-
tients who did and did not experience an event wereFIGURE 3 Spearman Correlation Analysis of OxPL-apoB and Lp(a)
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Correlation between OxPL-apoB and lipoprotein(a) (Lp[a]) is shown (A)
according to whether the patient experienced a major CV event; (C) at 1 y
patient experienced a major CV event. Abbreviations as in Figures 1 andnot signiﬁcant (p ¼ 0.24). Similar ﬁndings were pre-
sent in the changes of absolute levels of OxPL-apoB
(Figure 2B).
Spearman correlation analyses were carried out
between randomization and 1-year OxPL-apoB as well
as with Lp(a), which have been previously shown
to correlate with each other (18). OxPL-apoB at
randomization correlated with 1-year OxPL-apoB
(r ¼ 0.65; p < 0.0001) and Lp(a) at randomization
correlated with 1-year Lp(a) (r ¼ 0.94; p < 0.0001).
OxPL-apoB correlated with Lp(a) at randomization
(r ¼ 0.73; p < 0.0001) and at 1 year (r ¼ 0.71;
p < 0.0001) (Figure 3). Weak to absent correlations
were noted with lipid and laboratory variables in
Table 1 (data not shown).
DISCUSSION
This TNT trial substudy demonstrates that elevated
levels of OxPL-apoB predict secondary MACE in30
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CENTRAL ILLUSTRATION OxPLs, Statin Therapy, and CV Outcomes
(Top) The bar graph depicts the hazard or odds ratio of oxidized phospholipids on apolipoprotein B-100 (OxPL-apoB) for the primary endpoint in
each study indicated, comparing the highest to the lowest tertile or quartile. These studies included subjects without or with prior cardiovascular
disease (CVD), deﬁned as myocardial infarction, stroke, or peripheral arterial disease. The data are derived from prior publications including the
Bruneck Study (17), EPIC (European Prospective Investigation of Cancer)-Norfolk Trial (9), NHS (Nurses’ Health Study) and HPFS (Health Pro-
fessionals Follow-Up Study) (38), Mayo Study (11), and TNT (Treating to New Targets) trial. The Mayo Study (11) reﬂects the odds ratio for
angiographically-determined coronary artery disease. (Bottom) The illustration depicts the risk of CVDmediated by increased circulating levels of
OxPL-apoB in the context of intensity of statin therapy in patients with subclinical atherosclerosis, angiographically-determined coronary artery
disease (CAD), and CAD established by clinical criteria. As the intensity of statin therapy increases, the risk of new events (denoted by a ruptured
plaque on the cartoon) mediated by OxPL-apoB decreases, but is not completely abrogated. Lp(a) ¼ lipoprotein (a); MACE ¼ major adverse
cardiovascular event(s); OR ¼ odds ratio; qd ¼ daily. The OxPL-apoB assay reﬂects a combination of OxPL present on Lp(a) (w90%) and apoB
(w10%), denoted in the ﬁgure as OxPL on Lp(a) and OxPL on apoB, respectively.
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1293subjects with stable CHD. This was shown despite the
fact that, under this protocol, there was no placebo
arm and all patients were treated with atorvastatin
10 mg for 8 weeks prior to randomization, which has
known effects on OxPL-apoB (8). Importantly, it
suggests that high-dose treatment with atorvastatin
mitigates the risk conferred by OxPL-apoB. This study
expands upon the predictive power of OxPL-apoB for
CVD and clinical outcomes in primary prevention
settings to include statin-treated patients with
established CHD in the context of a contemporary
randomized clinical trial (Central Illustration).
It is well accepted that innate and adaptive immune
mechanisms modulate atherosclerosis. Immune re-
sponses to OSEs, such as OxPLs, play a central role in
the development of atherosclerosis (2). OxPLs are
proatherogenic and up-regulate proinﬂammatory
molecules in macrophages and endothelial cells (5).
OxPLs are present on Lp(a), both in the lipid phase and
covalently bound to apo(a), and the kringle IV type 10
segment of apo(a) strongly inﬂuences their binding
(6,19). OxPLs mediate macrophage apoptosis, a key
component of plaque vulnerability, in endoplasmic
reticulum-stressed macrophages by signaling through
the CD36/Toll-like receptor-2 pathway (20). Addi-
tionally, monocyte chemoattractant protein-1 binds to
OxPL on Lp(a) in human plasma, and once Lp(a) is
retained in the vessel wall, monocyte chemoattractant
protein-1 retains its ability to recruit monocytes, thus
promoting enhanced trafﬁcking into the vessel wall
(21). Finally, apo(a) and OxPL epitopes are signiﬁ-
cantly enriched in pathologically-deﬁned human
vulnerable plaques and clinically-relevant lesions that
require intervention, consistent with a clinically-
relevant pathological role in the expression of CVD
and events (3,13,14,22).
Extensive published data demonstrates that
elevated plasma levels of OxPL-apoB predict the
presence and progression of coronary, carotid, and
femoral/peripheral arterial disease; predict death,
myocardial infarction, and stroke in subjects from the
general community; and reclassify w30% of patients
into different risk categories (11). Lp(a) is also the
major lipoprotein carrier of OxPLs, which may impart
proinﬂammatory properties (6,7). The risk of Lp(a) is
strongly associated with its content of OxPLs, which
in turn are greatly enriched in small apo(a) isoforms
that are associated with the highest plasma Lp(a)
levels (18). Indeed, elevated plasma levels of
OxPL-apoB are associated with acute coronary syn-
dromes and increase post–percutaneous coronary in-
terventions (23,24).
Several therapeutic interventions increaseOxPL-apoB
levels, including low-fat diets, garlic supplements,andmost statins, as noted here in the TNT trial; we
emphasize that these are absolute levels and not a
ratio of OxPL to apoB levels measured in plasma.
The initial hypothesis was that OxPL-apoB and
Lp(a) levels would increase during hypercholester-
olemia and atherosclerosis progression and would
decrease during atherosclerosis regression in ani-
mals. Similarly, it was thought that OxPL-apoB
and Lp(a) levels would decrease during therapies
that caused regression in animal models or during
low-fat diets in humans. Surprisingly, and para-
doxically, we have observed the opposite to date;
namely, there have been increases in plasma OxPL-
apoB in New Zealand white rabbits and cynomolgus
monkeys on regression diets (25). Similarly, we
observed increases in both OxPL-apoB and its
carrier Lp(a) in humans on low-fat diets (26,27),
on Step II American Heart Association diets
(28), following statin therapy (28–33), or after
administration of aged garlic supplements in sub-
jects with CAD on a background of statin therapy
(34,35).
These data demonstrate that the increase in OxPL-
apoB and Lp(a) that occurred in response to various
interventions was associated with regression of
atherosclerosis in experimental models and with
improvement in vascular function and a reduced
rate of progression of coronary calciﬁcation in
humans (34,35). Although the mechanisms of the
increase in OxPL-apoB in plasma in response
to effective therapy are not understood yet,
immunostaining of atherosclerotic lesions for their
content of OxPL at baseline and after dietary-
induced lesion regression in New Zealand white
rabbits and cynomolgus monkeys showed loss of
OxPL in atherosclerotic plaques concomitantly with
an increase in OxPL-apoB levels in the plasma. This
is consistent with an efﬂux of OxPL from the vessel
wall to the circulation, where it was bound to apoB-
containing lipoproteins such as Lp(a), and suggests
the hypothesis of a potential stabilization or regres-
sion of lesions (25). Presumably, if one followed such
subjects for sufﬁcient periods of time in the future,
the OxPL-apoB levels would revert to lower levels,
thus explaining the ability of baseline OxPL-apoB
levels to predict cardiovascular outcomes. A second
possibility is that OxPL-apoB may increase along
with Lp(a) increases induced by statin therapy (8).
Interestingly, if one directly reduces Lp(a) in plasma,
as has been shown recently with antisense therapy
to apo(a) in both transgenic-Lp(a) mice (36) and
humans (37), then OxPL-apoB levels decrease sub-
stantially and in proportion to the decrease in the
carrier Lp(a).
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1294STUDY LIMITATIONS. This is a TNT substudy, and
the number of events was modest (n ¼ 156) compared
with the overall trial (n ¼ 982) (15). Blood samples
were not available prior to randomization, and it is
likely that 8 weeks of atorvastatin therapy affected
the levels of OxPL-apoB, which may have attenuated
its full predictive power.PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Pa-
tients with CVD who have elevated OxPL-apoB levels
are at high risk of ischemic events. High-dose, but not
low-dose, statin therapy reduces the risk mediated by
OxPLs.
TRANSLATIONAL OUTLOOK: Future studies
should assess the value of measuring OxPL-apoB
levels to risk-stratify patients for ischemic events and
guide statin dosing.CONCLUSIONS
OxPL-apoB levels are elevated in patients with sub-
sequent MACE, and these levels also predict second-
ary MACE in subjects with stable CHD, a risk that is
mitigated by high-dose (80 mg) atorvastatin. Elevated
levels of OxPL-apoB appear to be a clinically-
informative biomarker in predicting MACE in sec-
ondary care prevention settings.
ACKNOWLEDGMENTS Assistance in preparing the
tables and ﬁgures was provided by Shuang Li, PhD, at
Engage Scientiﬁc Solutions.REPRINT REQUESTS AND CORRESPONDENCE: Dr.
Sotirios Tsimikas, Vascular Medicine Program, Uni-
versity of California San Diego, 9500 Gilman Drive,
BSB 1080, La Jolla, California 92093-0682. E-mail:
stsimikas@ucsd.edu.RE F E RENCE S1. Witztum JL, Lichtman AH. The inﬂuence of
innate and adaptive immune responses on
atherosclerosis. Annu Rev Pathol 2014;9:73–102.
2. Miller YI, Choi SH, Wiesner P, et al. Oxidation-
speciﬁc epitopes are danger-associated molecular
patterns recognized by pattern recognition re-
ceptors of innate immunity. Circ Res 2011;108:
235–48.
3. van Dijk RA, Kolodgie F, Avandia A, et al.
Differential expression of oxidation-speciﬁc
epitopes and apolipoprotein(a) in progressing
and ruptured human coronary and carotid
atherosclerotic lesions. J Lipid Res 2012;53:
2773–90.
4. Lee S, Baranov KG, Romano ski CE,
Springstead JR, Luis AJ, Berliner JA. Role of
phospholipid oxidation products in atheroscle-
rosis. Circ Res 2012;111:778–99.
5. Kadl A, Sharma PR, Chen W, et al. Oxidized
phospholipid-induced inﬂammation is mediated by
Toll-like receptor 2. Free Rad Biol Med 2011;51:
1903–9.
6. Bergmark C, Dewan A, Orsoni A, et al. A novel
function of lipoprotein [a] as a preferential carrier
of oxidized phospholipids in human plasma. J Lipid
Res 2008;49:2230–9.
7. Leibundgut G, Scipione C, Yin H, et al. De-
terminants of binding of oxidized phospholipids on
apolipoprotein (a) and lipoprotein (a). J Lipid Res
2013;54:2815–30.
8. Taleb A, Witztum JL, Tsimikas S. Oxidized
phospholipids on apolipoprotein B-100 (OxPL/
apoB) containing lipoproteins: a biomarker pre-
dicting cardiovascular disease and cardiovascular
events. Biomarkers Med 2011;5:673–94.
9. Tsimikas S, Mallat Z, Talmud PJ, et al. Oxida-
tion-speciﬁc biomarkers, lipoprotein(a), and risk offatal and nonfatal coronary events. J Am Coll
Cardiol 2010;56:946–55.
10. Tsimikas S, Hall JH. Lipoprotein(a) as a po-
tential causal genetic risk factor of cardiovascular
disease: a rationale for increased efforts to un-
derstand its pathophysiology and develop tar-
geted therapies. J Am Coll Cardiol 2012;60:716–21.
11. Tsimikas S, Duff GW, Berger PB, et al. Pro-
inﬂammatory interleukin-1 genotypes potentiate
the risk of coronary artery disease and cardiovas-
cular events mediated by oxidized phospholipids
and lipoprotein(a). J Am Coll Cardiol 2014;63:
1724–34.
12. Friedman P, Horkko S, Steinberg D,
Witztum JL, Dennis EA. Correlation of anti-
phospholipid antibody recognition with the
structure of synthetic oxidized phospholipids.
Importance of Schiff base formation and aldol
condensation. J Biol Chem 2002;277:7010–20.
13. Choi SH, Yin H, Ravandi A, et al. Poly-
oxygenated cholesterol ester hydroperoxide acti-
vates TLR4 and SYK dependent signaling in
macrophages. PLoS One 2013;8:e83145.
14. Ravandi A, Leibundgut G, Hung MY, et al.
Release and capture of bioactive oxidized phos-
pholipids and oxidized cholesteryl esters during
percutaneous coronary and peripheral arterial in-
terventions in humans. J Am Coll Cardiol 2014;63:
1961–71.
15. LaRosa JC, Grundy SM, Waters DD, et al.
Intensive lipid lowering with atorvastatin in pa-
tients with stable coronary disease. N Engl J Med
2005;352:1425–35.
16. Arsenault BJ, Barter P, DeMicco DA, et al. Pre-
diction of cardiovascular events in statin-treated
stable coronary patients of the treating to
new targets randomized controlled trial by lipidand non-lipid biomarkers. PLoS One 2014;9:
e114519.
17. Tsimikas S, Willeit P, Willeit J, et al.
Oxidation-speciﬁc biomarkers, prospective 15-year
cardiovascular and stroke outcomes, and net
reclassiﬁcation of cardiovascular events. J Am Coll
Cardiol 2012;60:2218–29.
18. Tsimikas S, Clopton P, Brilakis ES, et al. Rela-
tionshipofoxidizedphospholipidsonapolipoprotein
B-100 particles to race/ethnicity, apolipoprotein(a)
isoform size, and cardiovascular risk factors: results
from the Dallas Heart Study. Circulation 2009;119:
1711–9.
19. Leibundgut G, Witztum JL, Tsimikas S. Oxida-
tion-speciﬁc epitopes and immunological re-
sponses: Translational biotheranostic implications
for atherosclerosis. Curr Opin Pharmacol 2013;13:
168–79.
20. Seimon TA, Nadolski MJ, Liao X, et al.
Atherogenic lipids and lipoproteins trigger CD36-
TLR2-dependent apoptosis in macrophages un-
dergoing endoplasmic reticulum stress. Cell Metab
2010;12:467–82.
21. Wiesner P, Tafelmeier M, Chittka D, et al. MCP-1
binds tooxidizedLDLand is carriedby lipoprotein(a)
in human plasma. J Lipid Res 2013;54:1877–83.
22. Purushothaman KR, Purushothaman M,
Levy AP, et al. Increased expression of oxidation-
speciﬁc epitopes and apoptosis are associated
with haptoglobin genotype: possible implications
for plaque progression in human atherosclerosis.
J Am Coll Cardiol 2012;60:112–9.
23. Tsimikas S, Bergmark C, Beyer RW, et al.
Temporal increases in plasma markers of oxidized
low-density lipoprotein strongly reﬂect the pres-
ence of acute coronary syndromes. J Am Coll
Cardiol 2003;41:360–70.
J A C C V O L . 6 5 , N O . 1 3 , 2 0 1 5 Byun et al.
A P R I L 7 , 2 0 1 5 : 1 2 8 6 – 9 5 Oxidized Phospholipids, Statin Therapy, and CV Outcomes
129524. Tsimikas S, Lau HK, Han KR, et al. Percutaneous
coronary intervention results in acute increases in
oxidized phospholipids and lipoprotein(a): short-
term and long-term immunologic responses to
oxidized low-density lipoprotein. Circulation 2004;
109:3164–70.
25. Tsimikas S, Aikawa M, Miller FJ Jr., et al.
Increased plasma oxidized phospholipid:
apolipoprotein B-100 ratio with concomitant
depletion of oxidized phospholipids from athero-
sclerotic lesions after dietary lipid-lowering: a
potential biomarker of early atherosclerosis
regression. Arterioscler Thromb Vasc Biol 2007;
27:175–81.
26. Faghihnia N, Tsimikas S, Miller ER, Witztum JL,
Krauss RM. Changes in lipoprotein(a), oxidized
phospholipids, and LDL subclasses with a low-fat
high-carbohydrate diet. J Lipid Res 2010;51:
3324–30.
27. Silaste ML, Rantala M, Alfthan G, et al.
Changes in dietary fat intake alter plasma levels of
oxidized low-density lipoprotein and lipo-
protein(a). Arterioscler Thromb Vasc Biol 2004;
24:498–503.
28. Rodenburg J, Vissers MN, Wiegman A, et al.
Oxidized low-density lipoprotein in children with
familial hypercholesterolemia and unaffected
siblings: effect of pravastatin. J Am Coll Cardiol
2006;47:1803–10.29. Tsimikas S, Witztum JL, Miller ER, et al. High-
dose atorvastatin reduces total plasma levels of
oxidized phospholipids and immune complexes
present on apolipoprotein B-100 in patients with
acute coronary syndromes in the MIRACL trial.
Circulation 2004;110:1406–12.
30. Ky B, Burke A, Tsimikas S, et al. The inﬂuence
of pravastatin and atorvastatin on markers of
oxidative stress in hypercholesterolemic humans.
J Am Coll Cardiol 2008;51:1653–62.
31. Choi SH, Prasad A, Tsimikas S. The evolution of
thienopyridine therapy clopidogrel duration, dia-
betes, and drug-eluting stents. J Am Coll Cardiol
2008;51:2228–9.
32. Fraley AE, Schwartz GG, Olsson AG, et al.
Relationship of oxidized phospholipids and bio-
markers of oxidized low-density lipoprotein with
cardiovascular risk factors, inﬂammatory bio-
markers, and effect of statin therapy in patients
with acute coronary syndromes: results from the
MIRACL (Myocardial Ischemia Reduction With
Aggressive Cholesterol Lowering) trial. J Am Coll
Cardiol 2009;53:2186–96.
33. Yoshida H, Shoda T, Yanai H, et al. Effects of
pitavastatin and atorvastatin on lipoprotein
oxidation biomarkers in patients with dyslipidemia.
Atherosclerosis 2013;226:161–4.
34. Budoff MJ, Ahmadi N, Gul KM, et al. Aged
garlic extract supplemented with B vitamins, folicacid and L-arginine retards the progression of
subclinical atherosclerosis: a randomized clinical
trial. Prev Med 2009;49:101–7.
35. Ahmadi N, Tsimikas S, Hajsadeghi F, et al.
Relation of oxidative biomarkers, vascular
dysfunction, and progression of coronary artery
calcium. Am J Cardiol 2010;105:459–66.
36. Merki E, Graham M, Taleb A, et al. Antisense
oligonucleotide lowers plasma levels of apolipo-
protein (a) and lipoprotein (a) in transgenic mice.
J Am Coll Cardiol 2011;57:1611–21.
37. Tsimikas S, Viney NJ, Hughes SG, et al.
Antisense therapy targeting apolipoprotein (a)
reduces plasma lipoprotein(a) Levels. Lancet
2015;In press.
38. Bertoia ML, Pai JK, Lee JH, et al. Oxidation-
speciﬁc biomarkers and risk of peripheral artery
disease. J Am Coll Cardiol 2013;61:2169–79.KEY WORDS atherosclerosis, biomarker,
coronary heart disease, inﬂammatory,
oxidation-speciﬁc epitopeAPPENDIX For further details of the
OxPL-apoB assay, please see the online
version of this article.
